Hepatitis Clinical Trials

Showing 1321-1340 of 2,113 trials

Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease

NCT02128503

This study aims to determine the prevalence of HBV infection in patients with IBD and rheumatologic disease, and to assess the impact of immunosuppressive therapy on viral load and clinical course of IBD patients.

Inflammatory Bowel DiseaseCrohn DiseaseUlcerative Colitis+2 more

Chinese University of Hong Kong430 participantsStarted Feb 2013

Hong Kong, Hong Kong

COMPLETED

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

NCT01590615

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Hepatitis B

Gilead Sciences54 participantsStarted Apr 2012

Los Angeles, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +24 more locations

Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

Related Searches

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years

Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts

Hepatitis B Vaccination in HIV-infected Adults

Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis

Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)

Biomarkers of Liver Fibrosis

An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys

An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)